Abstract
Background: Sentinel lymphadenectomy is highly accurate for identifying axillary metastasis from a primary breast carcinoma. Nonsentinel axillary lymph nodes (NSNs) are unlikely to contain tumor cells if the axillary sentinel node (SN) is tumor free. We previously showed that the size of the primary tumor and the size of its SN metastasis predict the risk of NSN tumor involvement detected by hematoxylin and eosin staining. This study used immunohistochemical staining (IHC) to determine the likelihood of NSN axillary metastasis in the presence of SN metastasis.
Methods: Between 1991 and 1997, axillary lymphadenectomy was performed in 156 women (157 axillary basins) who had primary breast carcinoma with SN metastasis. By hematoxylin and eosin staining, we identified NSN metastasis in 55 axillae (35%). IHC was then used to re-examine all NSNs (1827 lymph nodes) from the remaining 102 axillae. The incidence of IHC-detected NSN involvement was analyzed with respect to clinical and tumor characteristics.
Results: By using IHC, we identified NSN metastasis in 15 (14.7%) of the 102 axillae. By multivariate analysis, the size of the SN metastasis (P = .0001) and the size of the primary tumor (P = .038) were the only independent variables predicting NSN metastasis determined by using either hematoxylin and eosin staining or IHC. Only the number of SN metastases (1 vs. >1) was a significant (P = .04) predictor of IHC-detected NSN metastasis.
Conclusions: Use of IHC increases the likelihood of detection of NSN metastasis, and the risk of IHC-detected metastasis increases with the size of the SN metastasis and the size of the primary tumor. If SN involvement is micrometastatic (≤2 mm) or detected by using IHC, tumor cells are unlikely to be found in other axillary lymph nodes in patients with a small primary tumor. The clinical significance of micrometastatic disease in lymph nodes is controversial, and a prospective randomized study is necessary to resolve this important issue.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Cady B. Case against axillary lymphadenectomy for most patients with infiltrating breast cancer. J Surg Oncol 1997;66:7–10.
White RE, Vezeridis MP, Konstadoulakis M, Cole BF, Wanebo HJ, Bland KI. Therapeutic options and results for the management of minimally invasive carcinoma of the breast: influence of axillary dissection for treatment of T1a and T1b lesions. J Am Coll Surg 1996;183:575–582.
Chontos AJ, Maher DP, Ratzer ER, Fenoglio ME. Axillary lymph node dissection: is it required in T1a breast cancer? J Am Coll Surg 1997;184:493–498.
Fein DA, Fowble BL, Hanlon AL, et al. Identification of women with T1–T2 breast cancer at low risk of positive axillary nodes. J Surg Oncol 1997;65:34–39.
Whitten TM, Fraser HR, Christensen WN, Turk PS. Axillary lymph node metastasis in stage T1a breast cancer: a pathologic review of 82 patients. Am Surg 1997;63:144–149.
Giuliano AE, Barth AM, Spivack B, Beitsch PD, Evans SW. Incidence and predictors of axillary metastasis in T1 carcinoma of the breast. J Am Coll Surg 1996;183:185–189.
Shetty MR. Axillary lymph node metastasis in carcinoma of the breast. J Am Coll Surg 1997;184:671–673.
Giuliano AE, Jones RC, Brennan M, Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol 1997;15:2345–2350.
Turner RR, Ollila DW, Krasne DL, Giuliano AE. Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma. Ann Surg 1997;226:271–278.
Veronesi U, Paganelli G, Galimberti V, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 1997;349:1864–1867.
Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer: a multicenter validation study. N Engl J Med 1998;339:941–946.
Chu KU, Turner RR, Hansen N, Brennan M, Bilchik A, Giuliano AE. Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection? Ann Surg 1999;229:536–541.
Giuliano AE, Kirgan DM, Guenther M, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994;220:391–401.
Giuliano AE, Dale PS, Turner RR, Morton DL, Evans SW, Krasne DL. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 1995;222:394–401.
Fleming ID, Cooper JS, Henson DE, et al. AJCC Cancer Staging Manual. 5th ed. Philadelphia: Lippincott-Raven, 1997:171–180.
Clare SE, Sener SF, Wilkens W, Goldschmidt R, Merkel D, Winchester DJ. Prognostic significance of occult lymph node metastases in node-negative breast cancer. Ann Surg Oncol 1997;4:447–451.
Hainsworth PJ, Tjandra Stillwell RG, et al. Detection and significance of occult metastases in node-negative breast cancer. Br J Surg 1993;80:459–463.
Ludwig Breast Cancer Study Group. Prognostic importance of occult axillary lymph node micrometastases from breast cancers. Lancet 1990;335:1565–1568.
Dowlatshahi K, Fan M, Snider HC, Habib FA. Lymph node micrometastasis from breast carcinoma. Cancer 1997;80:1188–1197.
Wells CA, Heryet A, Brochier J, et al. The immunohistochemical detection of axillary micrometastases in breast cancer. Br J Cancer 1984;50:193–197.
Trojani M, de Mascarel I, Bonichon F, et al. Micrometastases to axillary lymph nodes from carcinoma of breast: detection by immunohistochemistry and prognostic significance. Br J Cancer 1987;55:303–306.
De Mascarel I, Bonichon F, Coindre JM, Trojani M. Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: reevaluation with longer follow-up. Br J Cancer 1992;66:523–527.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chu, K.U., Turner, R.R., Hansen, N.M. et al. Sentinel Node Metastasis in Patients with Breast Carcinoma Accurately Predicts Immunohistochemically Detectable Nonsentinel Node Metastasis. Ann Surg Oncol 6, 756–761 (1999). https://doi.org/10.1007/s10434-999-0756-2
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10434-999-0756-2